Question explored with the scientific record
Conversation so far
- 1 Stem cell treatments for Multiple
- 2 Stem cell treatments for Multiple Sclerosis patients Is it successful and safe
- 3 How do I know if my MS is a good fit for aHSCT?
- 4 MS can be confused with other autoimmune diseases such as Sarcoidosis and or Clippers
- 5 What tests best rule out neurosarcoidosis before considering aHSCT?
- 6 Should I delay aHSCT until a biopsy or PET scan is done?
Answered on this page ↓
Should I delay aHSCT until a biopsy or PET scan is done?
If there is real doubt about neurosarcoidosis, the biopsy or PET comes first. aHSCT is not a test you can undo.
The reason is what the chemo does to you. Conditioning wipes out your immune system and leaves you with a window of low white cells and slow T-cell recovery, and viral reactivations are common in that window [1][2]. If the true diagnosis is neurosarcoidosis, you would be giving powerful immune suppression to a granulomatous disease on a guess, and the treatment for sarcoidosis is different: steroids, with a documented survival difference in cardiac involvement [5].
PET earns its place here. FDG-PET detects cardiac sarcoidosis with pooled sensitivity up to 89% and specificity up to 78% [5], and cardiac involvement is the sarcoidosis complication that kills. A biopsy showing non-caseating granulomas is the confirming test [6][7]. Neither is perfect, and a negative result does not erase the suspicion.
| Test | What it adds | Limit |
|---|---|---|
| FDG-PET | Cardiac sarcoid, 89% sensitivity [5] | 78% specificity, false positives [5] |
| Biopsy | Non-caseating granulomas confirm [6][7] | Invasive, may miss the lesion [6] |
| MRI with contrast | Shows extent, guides biopsy [6] | Overlaps other diseases [7] |
The delay costs you little. aHSCT outcomes in MS were measured over years, not weeks [3][4]. A few weeks to settle the diagnosis does not forfeit the benefit.
My call: do the biopsy or PET first, then transplant. Confidence: moderate, because the sequencing itself was not studied, but the mechanism and the diagnostic stakes both point one way.
Sources used 7
-
Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy
This study investigates the impact of different myeloablative conditioning regimens (BEAM vs. Cy/TBI) on thymic activity and T cell repertoire recovery in lymphoma patients undergoing autologous hematopoietic stem cell transplantation, revealing that BEAM conditioning is associa…
DOI: 10.1016/j.bbmt.2016.01.014 -
Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay
This study investigates viral reactivations in 24 patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) using a multiplex PCR assay, revealing a significant incidence of reactivations, particularly of HHV-6 and EBV, with implications for patient moni…
DOI: 10.1002/jmv.24621 -
Autologous hematopoietic stem cell transplantation for MS
This study evaluates the safety and efficacy of autologous hematopoietic stem cell transplantation (aHSCT) for multiple sclerosis (MS), suggesting it may be safer and as effective as current disease-modifying drugs.
DOI: 10.1212/WNL.0000000000003995 -
Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis
An expert commentary reviewing the progress, mechanisms, regimens, and clinical implications of autologous hematopoietic stem cell transplantation (AHSCT) for multiple sclerosis, highlighting potential suppression of CNS inflammation and possible disability reversal alongside th…
DOI: 10.1080/1744666X.2017.1297232 -
Cardiac Sarcoidosis: Pathophysiology, Diagnosis, and Management
This review synthesizes evidence that timely use of ECG, echo, CMR, and FDG-PET is central to diagnosing cardiac sarcoidosis, and early immunosuppression and ICD risk stratification are key to management.
DOI: 10.3390/hearts2020019 -
Neurosarcoidosis With Extensive Opto-Chiasmatic and Meningeal Involvement: A Case Report
A rare neurosarcoidosis case with extensive opto-chiasmatic and leptomeningeal involvement demonstrated by MRI, illustrating MRI’s crucial role in delineating disease extent, guiding biopsy considerations, and monitoring response to immunosuppressive therapy.
DOI: 10.70780/medpeer.000qgpd -
Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes)
This article introduces the concept of brain–eye–ear (BEE) syndromes as a spectrum of immune-mediated diseases affecting the brain, eyes and ears, and provides a comprehensive, multidisciplinary review of their clinical features, diagnostic clues (imaging, CSF and ophthalmologic…
DOI: 10.1136/jnnp-2018-319002